 "Dishman Pharma's Swiss arm Carbogen Amcis to expand operations")
Dishman Pharmaceuticals and Chemicals’ Swiss arm Carbogen Amcis, which offers process development and manufacturing of active pharmaceutical ingredient (API) to the pharmaceutical industry, will expand its operations in Bubendorf (Switzerland).
For this, Carbogen Amcis has signed an agreement to acquire the land and buildings of GEA Pharma Systems AG in Bubendorf. The acquisition, which is close to its current headquarters and larger scale production site, will become effective on January 1, 2017.
The acquired space is divided into laboratory, production, storage and office areas and provides a set of clean-room GMP compliant suites. Carbogen Amcis is planning for modification work in order to adapt the building to its specific requirements and convert more of the facility into GMP operations areas. The acquisition will allow Carbogen Amcis to significantly expand its laboratory capacity for highly potent development and small scale production as well as analytical support.
“In the last couple of years we have experienced a significant and continuous increase in customers’ demand for additional capacity, including demand for labs and small scale development. This acquisition is targeted to support our business growth and company expansion. It will allow Carbogen Amcis to keep its position as an industry leader and outsourcing partner for complex highly potent APIs and ADCs (antibody drug conjugates),” said Janmejay Vyas, chairman of the Dishman Group of Companies, in a press release.
Mark Griffiths, Global CEO of Carbogen Amcis and the Dishman Group, added, “This facility will bring new opportunities to further enhance our capabilities and capacities. In the near future, the company plans to introduce a number of additional capabilities including, but not limited to, commercial manufacture of ADCs and additional Cat 4 (ng OEL) development capacity.”
Carbogen Amcis AG, owned by the Ahmedabad-based Dishman Pharmaceuticals and Chemicals Ltd, is a one of the leading service providers to to the pharmaceutical and biopharmaceutical industry offering a portfolio of drug development and commercialisation services at all stages of drug development.
Dishman Pharma is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. The Dishman Group improves its customers’ businesses by providing a range of development and manufacturing solutions at locations in Europe and in India.
For this, Carbogen Amcis has signed an agreement to acquire the land and buildings of GEA Pharma Systems AG in Bubendorf. The acquisition, which is close to its current headquarters and larger scale production site, will become effective on January 1, 2017.
The acquired space is divided into laboratory, production, storage and office areas and provides a set of clean-room GMP compliant suites. Carbogen Amcis is planning for modification work in order to adapt the building to its specific requirements and convert more of the facility into GMP operations areas. The acquisition will allow Carbogen Amcis to significantly expand its laboratory capacity for highly potent development and small scale production as well as analytical support.
“In the last couple of years we have experienced a significant and continuous increase in customers’ demand for additional capacity, including demand for labs and small scale development. This acquisition is targeted to support our business growth and company expansion. It will allow Carbogen Amcis to keep its position as an industry leader and outsourcing partner for complex highly potent APIs and ADCs (antibody drug conjugates),” said Janmejay Vyas, chairman of the Dishman Group of Companies, in a press release.
Mark Griffiths, Global CEO of Carbogen Amcis and the Dishman Group, added, “This facility will bring new opportunities to further enhance our capabilities and capacities. In the near future, the company plans to introduce a number of additional capabilities including, but not limited to, commercial manufacture of ADCs and additional Cat 4 (ng OEL) development capacity.”
Carbogen Amcis AG, owned by the Ahmedabad-based Dishman Pharmaceuticals and Chemicals Ltd, is a one of the leading service providers to to the pharmaceutical and biopharmaceutical industry offering a portfolio of drug development and commercialisation services at all stages of drug development.
Dishman Pharma is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. The Dishman Group improves its customers’ businesses by providing a range of development and manufacturing solutions at locations in Europe and in India.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%